Efficacy and safety of early administration of remdesivir in hemodialysis patients with COVID-19: A case report and literature review

Nanako Oshiro,Takeshi Kinjo,Daigo Aharen,Yuki Kudo,Eisuke Katsuren,Kumiko Omine,Takuto Nakamura,Ryo Zamami,Akio Ishida,Kazuya Miyagi,Masashi Nakamatsu,Kazuko Yamamoto,Kenya Kusunose,Jiro Fujita,Yusuke Ohya,Kentaro Kohagura
DOI: https://doi.org/10.1097/md.0000000000040650
IF: 1.6
2024-12-01
Medicine
Abstract:As the virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) declined and the antiviral strategy such as vaccine and antiviral drugs developed, mortality rate of coronavirus disease 2019 (COVID-19) has decreased recently. [ 1 , 2 ] However, COVID-19 can be still critical for patients with risk factors including hemodialysis (HD). [ 3 ] Patients on HD are particularly vulnerable to severe COVID-19 because they are often older age and have many comorbidities such as hypertension and diabetes. According to large studies conducted before the emergence of the Omicron variant, the mortality rate among HD patients with COVID-19 was 20 to 26%. [ 4–6 ] In terms of Japanese HD patients, the mortality was reported to be 31%, which was 20 times higher than that of the general population (1.5%). [ 7 ] Although the mortality has declined during the Omicron phase, the rate for HD patients was still high compared to general population. [ 8 , 9 ] Beppu, et al [ 8 ] reported the mortality rate for HD patients with COVID-19 was changed from 16% to 4% between pre-Omicron and Omicron phase, thus the rate has decreased but remains high. Additionally, patients receiving in-center HD are always exposed to the risk of SARS-CoV-2 infection and involvement of nosocomial cluster. One study showed that patients receiving in-center HD had an approximately 2-fold greater risk of SARS-CoV-2 infection compared to patients receiving home dialysis. [ 5 ]
medicine, general & internal
What problem does this paper attempt to address?